JP2022522776A5 - - Google Patents
Info
- Publication number
- JP2022522776A5 JP2022522776A5 JP2021551770A JP2021551770A JP2022522776A5 JP 2022522776 A5 JP2022522776 A5 JP 2022522776A5 JP 2021551770 A JP2021551770 A JP 2021551770A JP 2021551770 A JP2021551770 A JP 2021551770A JP 2022522776 A5 JP2022522776 A5 JP 2022522776A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dose
- pharmaceutical composition
- composition according
- vector genome
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813597P | 2019-03-04 | 2019-03-04 | |
| US62/813,597 | 2019-03-04 | ||
| US201962839457P | 2019-04-26 | 2019-04-26 | |
| US62/839,457 | 2019-04-26 | ||
| PCT/US2020/020929 WO2020180951A1 (en) | 2019-03-04 | 2020-03-04 | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522776A JP2022522776A (ja) | 2022-04-20 |
| JP2022522776A5 true JP2022522776A5 (https=) | 2023-03-13 |
| JP7597380B2 JP7597380B2 (ja) | 2024-12-10 |
Family
ID=70334029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021551770A Active JP7597380B2 (ja) | 2019-03-04 | 2020-03-04 | 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200297869A1 (https=) |
| EP (1) | EP3934698A1 (https=) |
| JP (1) | JP7597380B2 (https=) |
| KR (1) | KR20210135267A (https=) |
| AU (1) | AU2020231505A1 (https=) |
| WO (1) | WO2020180951A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN114250227B (zh) * | 2020-09-25 | 2026-04-03 | 北京安龙生物医药有限公司 | 用于高水平表达外源基因的表达载体 |
| JP2023550548A (ja) * | 2020-11-10 | 2023-12-01 | アビラマックス・バイオファーマ・インコーポレイテッド | 操作されたウイルスカプシドおよび使用方法 |
| BR112023020490A2 (pt) * | 2021-04-09 | 2023-11-21 | Avirmax Biopharma Inc | Composições e métodos para expressão de transgenes oculares |
| AU2023220219A1 (en) | 2022-02-17 | 2024-09-05 | Skyline Therapeutics Limited | Recombinant adeno-associated virus with modified aav capsid polypeptides |
| JP2025519378A (ja) | 2022-06-07 | 2025-06-26 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 視覚回復のためのメラノプシンバリアント |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024168252A2 (en) * | 2023-02-10 | 2024-08-15 | Yale University | Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053703A2 (en) * | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9725485B2 (en) * | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| LT3137497T (lt) * | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| US11021519B2 (en) * | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| AU2017257169B2 (en) * | 2016-04-29 | 2021-07-08 | Adverum Biotechnologies, Inc. | Evasion of neutralizing antibodies by a recombinant adeno-associated virus |
| ES2840059T3 (es) * | 2016-06-16 | 2021-07-06 | Adverum Biotechnologies Inc | Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept |
| CA3040179A1 (en) * | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| JP2020510424A (ja) * | 2017-02-28 | 2020-04-09 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | 改変ａａｖカプシドおよびその使用 |
| EP4653536A3 (en) | 2017-03-17 | 2026-02-25 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
-
2020
- 2020-03-04 JP JP2021551770A patent/JP7597380B2/ja active Active
- 2020-03-04 WO PCT/US2020/020929 patent/WO2020180951A1/en not_active Ceased
- 2020-03-04 US US16/808,932 patent/US20200297869A1/en not_active Abandoned
- 2020-03-04 EP EP20720552.7A patent/EP3934698A1/en not_active Withdrawn
- 2020-03-04 AU AU2020231505A patent/AU2020231505A1/en active Pending
- 2020-03-04 KR KR1020217031241A patent/KR20210135267A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022522776A5 (https=) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2021503914A5 (https=) | ||
| CN113766934B (zh) | 用于玻璃体内递送的变体aav衣壳 | |
| JP2022529775A5 (https=) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| US20190142975A1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| CN113121652A (zh) | 视网膜和肌肉高亲和性腺相关病毒衣壳蛋白及相关应用 | |
| CN117467025B (zh) | 一种抗vegf和补体双功能融合蛋白及其应用 | |
| JP7842082B2 (ja) | 眼疾患を処置するための組成物および方法 | |
| JP2022523679A (ja) | 体液性免疫を回避する組成物および方法 | |
| RU2018143411A (ru) | Лечение комплемент-опосредуемых расстройств | |
| US20250340900A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| JP2021511030A5 (https=) | ||
| CN110423281A (zh) | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 | |
| JP2023545229A5 (https=) | ||
| WO2023125481A1 (zh) | 经过修饰的aav衣壳蛋白及其用途 | |
| WO2018057916A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| CN114276419B (zh) | 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用 | |
| CN113121655A (zh) | 眼部和肌肉特异靶向型腺相关病毒载体及其应用 | |
| WO2022222869A1 (zh) | 重组腺相关病毒及其应用 | |
| JP2025506681A5 (https=) | ||
| TW202508610A (zh) | 醫藥組成物及其用途 | |
| CN117085148A (zh) | 一种治疗眼病或病症的方法 | |
| CN114828857B (zh) | 通过激活tfeb恢复视网膜色素上皮细胞的溶酶体功能的方法 |